# A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

> **NCT07712939** · PHASE1 · RECRUITING · sponsor: **Candid Therapeutics** · enrollment: 105 (estimated)

## Conditions studied

- Healthy Participants Study
- Rheumatoid Arthritis
- Sjogren's Syndrome

## Interventions

- **BIOLOGICAL:** CND319

## Key facts

- **NCT ID:** NCT07712939
- **Lead sponsor:** Candid Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712939, "A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07712939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*